non-small cell lung cancer

Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Endpoints
Merck
Keytruda
Yervoy
clinical trials
non-small cell lung cancer
Flag link:
Jounce shares crash after it abandons immunotherapy combination trial
Jounce shares crash after it abandons immunotherapy combination trial
Pharmaforum
Jounce Therapeutics
non-small cell lung cancer
Bristol-Myers Squibb
Yervoy
Flag link:
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Fierce Pharma
Regeneron
Sanofi
Libtayo
FDA
priority review
non-small cell lung cancer
Merck
Keytruda
Flag link:
Triple meeting – the point of turning to TPX-0022
Triple meeting – the point of turning to TPX-0022
EP Vantage
Turning Point Therapeutics
repotrectinib
TPX-0022
non-small cell lung cancer
Flag link:
Merck touts new data for Keytruda combos in NSCLC at North American conference
Merck touts new data for Keytruda combos in NSCLC at North American conference
Endpoints
Merck
clinical trials
Keytruda
non-small cell lung cancer
IASLC
Flag link:
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
BioSpace
Bristol-Myers Squibb
clinical trials
non-small cell lung cancer
Opdivo
Flag link:
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Fierce Biotech
Amgen
clinical trials
non-small cell lung cancer
KRAS
sotorasib
Flag link:
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
BioSpace
AstraZeneca
clinical trials
Tagrisso
ESMO
non-small cell lung cancer
Flag link:
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Flag link:
Amgen publishes, presents data on therapy with ‘undruggable’ target
Amgen publishes, presents data on therapy with ‘undruggable’ target
MedCity News
Amgen
sotorasib
ESMO
AMG 510
non-small cell lung cancer
Flag link:
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
Endpoints
AstraZeneca
Tagrisso
non-small cell lung cancer
ESMO
Flag link:
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Flag link:
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Endpoints
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
clinical trials
Pfizer
Roche
Flag link:
Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment
Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment
Stat
lung cancer
non-small cell lung cancer
targeted therapeutics
Flag link:
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
Fierce Pharma
Eli Lilly
Innovent Biologics
China
non-small cell lung cancer
Tyvyt
Merck
Keytruda
Flag link:
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Pharmaceutical Business Review
Daiichi Sankyo
AstraZeneca
patritumab deruxtecan
Tagrisso
non-small cell lung cancer
clinical trials
Flag link:
Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program
Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program
Endpoints
Elevation Oncology
Merrimack
seribantumab
non-small cell lung cancer
Flag link:
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
BioSpace
Merck
Novocure
clinical trials
tumor treating fields
Keytruda
non-small cell lung cancer
Flag link:
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
BioSpace
Daiichi Sankyo
Thermo Fisher
companion diagnostics
diagnostics
non-small cell lung cancer
Flag link:
NICE backs funding for Roche’s lung cancer drug after price cut
NICE backs funding for Roche’s lung cancer drug after price cut
Pharmaforum
NICE
Roche
Rozlytrek
non-small cell lung cancer
Flag link:

Pages